Literature DB >> 8341771

Hyperdopaminergia in schizophreniform psychosis: a chronobiological study.

M L Rao1, G Gross, A Halaris, G Huber, M Marler, B Strebel, P Bräunig.   

Abstract

Circadian rhythm abnormalities have been described in various psychiatric disorders, but they have not received much attention in studies of schizophrenia and schizophreniform psychosis. The present study used the cosine model to determine the circadian patterns of amino acids, dopamine, and prolactin concentrations, which were analyzed over a 24-hour period in serum of healthy subjects, drug-free schizophrenic patients, and neuroleptic-treated schizophrenic patients. The mesor (the daily mean) of phenylalanine was lower in drug-free schizophrenic women than in healthy women. The mesors of the ratio of phenylalanine or tyrosine to competing amino acids were similar in healthy subjects and patients. The ratio of phenylalanine/competing amino acids showed a phase advance (i.e., earlier onset of the time of highest concentration) in drug-free patients compared with healthy subjects. Schizophrenic patients displayed a higher dopamine mesor than healthy subjects. Female drug-free schizophrenic patients had lower prolactin mesors and lower amplitudes (i.e., half of the total predictable change in rhythm) than healthy women. Compared with healthy subjects, schizophrenic patients showed a phase advance of circadian prolactin concentrations. Neuroleptics raised the prolactin mesor and amplitudes but did not elicit any phase change in amino acids, dopamine, or prolactin. These data confirm the indirect pharmacologic evidence of increased dopaminergic activity in schizophrenic patients that relates to dopamine's precursors and to the neuroendocrine regulation of prolactin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341771     DOI: 10.1016/0165-1781(93)90048-l

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.

Authors:  Klas J Petersson; An M Vermeulen; Lena E Friberg
Journal:  AAPS J       Date:  2013-02-08       Impact factor: 4.009

Review 3.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.